1. Pink Sheet
  2. >>Product Reviews

Product Differences Necessitate Some US FDA Inconsistency In Rare Diseases, Center Directors Say

 
• By Derrick Gingery

Development standards for a one-time gene therapy should be different from a drug taken regularly, CBER Director Peter Marks says.

Consistency arrows
Inconsistency is not the same as scientific disagreement, CDER Director Patrizia Cavazzoni said. • Source: Shutterstock

Rare disease treatment sponsors and advocates may prefer all US Food and Drug Administration teams give the same development advice, but that may not be possible across all classes of products, regulators caution.

Inconsistent advice not only occurs within the FDA’s drug and biologic offices, but between the centers. Center for Biologics Evaluation...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

EMA Explores Supporting Drug Development For High Unmet Need Disorder Scleroderma

 
• By Neena Brizmohun

While treatments for scleroderma are in development, none are approved for the condition that is associated with high morbidity and mortality. The European Medicines Agency says guidance on how to design development programs for the disorder is needed.

EMA Nod For First MASH Drug Rezdiffra, Cell Therapy Zemcelpro And 11 Others

 
• By Eliza Slawther

Madrigal Pharmaceuticals’ Rezdiffra is on track to become the first medicine approved in the EU for non-cirrhotic metabolic dysfunction-associated steatohepatitis after the European Medicines Agency recommended that it be granted conditional marketing authorization.

BIO Notebook: Policy Uncertainty Constraining Dealmaking

 
• By Mandy Jackson and Joseph Haas

Highlights from Day Four of the BIO International Convention include policy concerns helping constrain dealmaking, Novartis discussing its approach to partnering, and Generate looking for funding to move into Phase III.